Analysts Set ABIVAX Société Anonyme (NASDAQ:ABVX) Price Target at $38.67

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have received an average recommendation of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $38.67.

A number of equities research analysts recently weighed in on ABVX shares. JMP Securities initiated coverage on ABIVAX Société Anonyme in a research report on Wednesday, December 4th. They set an “outperform” rating and a $33.00 target price on the stock. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th.

ABIVAX Société Anonyme Stock Performance

ABVX stock opened at $7.32 on Friday. The company has a 50-day moving average of $8.99 and a two-hundred day moving average of $10.83. ABIVAX Société Anonyme has a 52-week low of $6.53 and a 52-week high of $17.02.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. boosted its position in ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares in the last quarter. abrdn plc increased its holdings in ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Walleye Capital LLC increased its holdings in ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.